Re-engineering Drug Discovery and Development
Loading...
Penn collection
Issue Briefs
Degree type
Discipline
Subject
medical technology
pharmaceuticals
Medicinal-Pharmaceutical Chemistry
pharmaceuticals
Medicinal-Pharmaceutical Chemistry
Funder
Grant number
Copyright date
Distributor
Author
FitzGerald, Garret A
Contributor
Abstract
The rate of new drug approvals in the US has remained essentially constant since 1950, while the costs of drug development have soared. Many commentators question the sustainability of the current model of drug development, in which large pharmaceutical companies incur markedly escalating costs to deliver the same number of products to market. This Issue Brief summarizes the problem, describes ongoing governmental efforts to influence the process, and suggests changes in regulatory science and translational medicine that may promote more successful development of safe and effective therapeutics.
Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2011-10-10